Mylan Inc - MYL - reported that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the FDA for its Abbreviated New Drug Application for Eprosartan Mesylate Tablets, 400 mg (base) and 600 mg (base), which are used to treat hypertension.
